特約創新團隊介紹

團隊負責人介紹

沈南 SHEN Nan

教授、主任醫師、博士生導師

MD, Ph.D, Professor, Chief Physician, Doctoral Supervisor ORCID ID：0000-0002-5875-4417

創新團隊名稱

自身免疫病精準診治新策略研究

團隊主要成員

沈南(研究員/博士) 黃傳新(研究員/博士) 李福彬(研究員/博士)余迪(研究員/博士) 唐元家(研究員/博士) 扶瓊(副主任醫師/博士)周海波（副研究員/博士） 鄧軍（副研究員/博士） 曲波（副研究員/博士）

沈南（1965—），國家“973”計劃首席科學家，上海交通大學特聘教授。1988年畢業于上海交通大學醫學院(原上海第二醫科大學),2012年獲得荷蘭阿姆斯特丹大學博士學位。1998—1999年在美國加州大學洛杉磯分校進行訪問研究。現任上海市風濕病學研究所所長、上海交通大學醫學院附屬仁濟醫院風濕科主任、中澳個體化自身免疫病研究中心主任。現任上海市醫學會風濕病分會副主委、全國臨床免疫學會委員、上海免疫學會副理事長、上海免疫學會風濕免疫專業委員會主任委員、Faculty of 1000專家成員、美國風濕病學會策劃委員會委員（亞太地區唯一委員）、亞太地區風濕病學聯盟科學顧問委員會委員、國際紅斑狼瘡遺傳學研究協作組成員。目前擔任Arthritis and Rheumatology、Arthritis Research & Therapy、International Journal of Rheumatic Diseases雜志副主編，Annals of Rheumatic Diseases、Clinical Immunology、Clinical Rheumatology雜志編委，系統性紅斑狼瘡權威教科書 Dubois' Lupus Erythematosus and Related Syndromes（Eighth edition）副主編。

沈南教授長期致力于系統性紅斑狼瘡的發病機制和特異性干預治療等科研工作，取得了多項突破性研究成果。承擔多項國家級及省部級科研任務，主持國家 “973”計劃項目1項、國家“863”計劃項目1項、國家自然科學基金重點項目3項、上海市科委重點項目2項，并得到上海市領軍人才等人才項目支持。

SHEN Nan(1965—), “973 Program” chief scientist, distinguished professor of Shanghai Jiao Tong University. Prof. SHEN graduated from Shanghai Jiao Tong University School of Medicine in 1988 and received his doctorate from University of Amsterdam in Netherlands in 2012. He was a visiting researcher at University of California, Los Angeles from 1998 to 1999. He is director of Shanghai Institute of Rheumatology, director of Department of Rheumatology of Renji Hospital, Shanghai Jiao Tong University School of Medicine, and co-executive director of China-Australia Centre for Personalized Immunology. Currently, he is vice-chairman of the rheumatology branch of Shanghai Medical Association, a member of National Clinical Immunology Society, vice-chairman of Shanghai Immunology Society, chairman of Professional Committee of Rheumatology of Shanghai Immunology Society, a member of Planning Committee of ACR Annual Meeting (the only member in the Asia-Pacific region), a faculty member of Faculty of 1 000, a member of Scientific Advisory Board of Asia Pacific League of Associations for Rheumatology, and a member of International Collaborative Group on Lupus Genetics. He is currently an associate editor of Arthritis and Rheumatology, Arthritis Research & Therapy, International Journal of Rheumatic Diseases, and an editorial board member of Annals of Rheumatic Diseases, Clinical Immunology, and Clinical Rheumatology, and he is deputy editor of an authoritative textbook on systemic lupus erythematosus—Dubois' Lupus Erythematosus and Related Syndromes (Eighth edition).

Prof. SHEN is focusing on the pathogenesis and specific intervention therapy of systemic lupus erythematosus and has made significant progress in this field. He is responsible for several scientific research tasks at the national and provincial levels, among which he presides one “973” Program, one “863” Project, three key projects of National Natural Science Foundation of China and two key projects of Shanghai Municipal Science and Technology Commission. He was supported by Shanghai's Leading Talent Program.

主要研究方向

沈南教授研究組在國際上率先解析多個非編碼RNA在系統性紅斑狼瘡關鍵指標通路中的重要調控作用及其與重要靶器官受累的關系，取得了豐碩的研究成果，受到了國際同行的廣泛關注和認可。在Nature Medicine、Nature Genetics、Immunity、Plos genetics、Blood、PNAS等國際著名學術期刊上發表SCI論文100余篇，被引用8 800余次， h指數為46；其中9篇論文在風濕病學最有影響力的雜志上發表，4篇同刊同期附有特約評論，3篇被Faculty of 1000收錄并評述4次。

Prof. SHEN 's research group was the first to analyze the role of several non-coding RNAs in the pathogenesis of systemic lupus erythematosus and their relationship with the involvement of important target organs. Prof. SHEN 's group has made important progress in systemic lupus erythematosus. The group has published more than 100 papers in Nature Medicine, Nature Genetics, Immunity, PLoS Genetics, Blood, PNAS,etc, with a total citation of more than 8 800 times and h-index of 46, Nine of these papers were published in the most influential journals of rheumatology, four papers were featured in the same issue, and three were included in Faculty of 1 000 and reviewed for four times.

近2年代表性成果

1) Li G, Ding H, Yu X, et al. Spermidine suppresses inflammatory DC function by activating the FOXO3 pathway and counteracts autoimmunity[J].iScience, 2020, 23(1)：100807.

2) Zhang W, Zhang H, Liu S, et al. Excessive CD11c+Tbet+B cells promote aberrant TFH differentiation and affinity-based germinal center selection in lupus[J]. Proc Nat Acad Sci, 2019, 116(37): 18550-18560.

3) Liu CX, Li X, Nan F, et al. Structure and degradation of circular RNAs regulate PKR activation in innate immunity[J]. Cell, 2019, 177(4): 865-880.

4) Wu C, Fu Q, Guo Q, et al. Lupus-associated atypical memory B cells are mTORC1-hyperactivated and functionally dysregulated[J]. Ann Rheum Dis,2019, 78(8): 1090-1100.

5) Wang J, Dai M, Cui Y, et al. Association of abnormal elevations in IFIT3 with overactive cyclic GMP-AMP synthase/stimulator of interferon genes signaling in human systemic lupus erythematosus monocytes[J]. Arthr Rheum, 2018, 70(12): 2036-2045.

6) Deng J, Fan C, Gao X, et al. Signal transducer and activator of transcription 3 hyperactivation associates with follicular helper T cell differentiation and disease activity in rheumatoid arthritis[J]. Front Immunol, 2018, 9: 1226.

7) Zeng J, Meng X, Zhou P, et al. Interferon-α exacerbates neuropsychiatric phenotypes in lupus-prone mice[J]. Arthr Res Ther, 2019, 21(1): 205.

8) Deng J, Wei Y, Fonseca VR, et al. T follicular helper cells and T follicular regulatory cells in rheumatic diseases[J]. Nat Rev Rheumatol, 2019,15(8): 475-490.